Insulet Corporation (PODD)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$2.12 (-0.79%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Insulet Corporation (PODD)
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Key Insights

Critical company metrics and information

  • Share Price

    $265.46

  • Market Cap

    $18.62 Billion

  • Total Outstanding Shares

    70.15 Million Shares

  • Total Employees

    3,000

  • Dividend

    No dividend

  • IPO Date

    May 15, 2007

  • SIC Description

    Surgical & Medical Instruments & Apparatus

  • Homepage

    https://www.insulet.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$-109.80 Million
Net Cash Flow$217.20 Million
Exchange Gains/Losses$4.20 Million
Net Cash Flow, Continuing$213.00 Million
Net Cash Flow From Investing Activities, Continuing$-109.80 Million
Net Cash Flow From Operating Activities$327.80 Million
Net Cash Flow From Financing Activities, Continuing$-5.00 Million
Net Cash Flow From Financing Activities$-5.00 Million
Net Cash Flow From Operating Activities, Continuing$327.80 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss$420.90 Million
Benefits Costs and Expenses$1.69 Billion
Income/Loss From Continuing Operations Before Tax$296.70 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Parent$420.90 Million
Operating Expenses$1.07 Billion
Selling, General, and Administrative Expenses$869.00 Million
Research and Development$201.00 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income/Loss From Continuing Operations After Tax$420.90 Million
Costs And Expenses$1.69 Billion
Operating Income/Loss$306.00 Million
Basic Earnings Per Share$6.01
Cost Of Revenue$607.90 Million
Income Tax Expense/Benefit$-124.20 Million
Diluted Average Shares$77.35 Million
Basic Average Shares$70.08 Million
Revenues$1.98 Billion
Gross Profit$1.38 Billion
Net Income/Loss Available To Common Stockholders, Basic$420.90 Million
Diluted Earnings Per Share$5.87

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Current Liabilities$465.90 Million
Liabilities$1.91 Billion
Noncurrent Assets$1.16 Billion
Equity Attributable To Parent$1.12 Billion
Equity$1.12 Billion
Current Assets$1.86 Billion
Inventory$444.90 Million
Accounts Payable$40.30 Million
Other Current Assets$1.42 Billion
Noncurrent Liabilities$1.40 Billion
Assets$3.03 Billion
Equity Attributable To Noncontrolling Interest$0.00
Current Liabilities$506.20 Million
Liabilities And Equity$3.03 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.